SPEED RCT: In early PsA with poor prognostic factors, PASDAS at 24wks: •Early TNFi: 3.7 •Combo csDMARDs: 4.1 •Step-up csDMARDs: 4.7 Early TNFi beat step-up by -1.09 (p<0.001); combo csDMARDs also superior (-0.69, p=0.02). Early TNFi benefit sustained at 48wks. Abstract#OP0089 https://t.co/MpazF8BIr2

Precision immunotherapy in axial spondyloarthritis: TRBV9xCD3 bispecific antibodies selectively depleted autoreactive TRBV9+ T cells from HLA-B27+ AS patient samples while sparing over 95 percent of the T cell repertoire. TRBV9xCD3 bispecific antibodies selectively depleted https://t.co/8UXqEaDYnS

In vitro, balinatunfib (TNFR1-selective inhibitor) preserved Treg expansion in CD4+ T cells co-cultured with IL-2 and memTNF (Treg 8.99 percent, p<0.0001), unlike adalimumab and etanercept which reduced Tregs by 27.5 to 41 percent. Confirms TNFR2 sparing with selective TNFR1 https://t.co/xaczz87Xrd

Hepcidin detected in synovial membrane and fluid in RA, PsA, and OA. Monocytes were the main source. IL-6, IL-10, IL-17, M-CSF induced hepcidin via JAK-STAT pathway. Hepcidin reduced osteoclastogenesis but correlated with synovial neutrophils and CXCL1 induction. Functional dual https://t.co/ZjUtTYPre8

VEGF-Grab (PB101/PB102), dual VEGF/PlGF decoy receptor, inhibited angiogenesis, RA-FLS invasion, and Th17 cell differentiation in RA and MS models. PB102 reduced IL-17 and GM-CSF co-expressing Th17 cells, suppressed pannus and joint destruction in CIA, and outperformed IFN-β in https://t.co/qhVRYT4RbK

#EULAR2025 Abstr#OP0002 Promising new mode of action therapy for #myositis. Phase 2 RCT of efgartigimod (FcRn-i; coformulated with recombinant PH20) showed improvement in TIS & other key endpoints vs PBO at Wk24. Injection reaction common (23%). Will proceed to Phase 3 @RheumNow https://t.co/SuMolfcDkS

Pain & age predict outcomes in #osteoarthritis In a #cohort of 92 pts with #knee #OA Factors were studied for response Better ✅#NSAIDs or #acetaminophen v #opiates ✅Older ✅Lower #WOMAC PAIN & no sensitization 🤔help RCT inclusion #EULAR2025 @RheumNow POS0612 @eular_org https://t.co/9I2JN9sgUe

Cool technology reduces dose interval of #IL17AFi To…every 6 to 12 months! #Antibody ORKA-002 has end of arms w YTE substitution prolonging circulation of drug Lasts longer than #bimekizumab Easier for adherence! #EULAR2025 @RheumNow @eular_org #abstPOS0016 https://t.co/KcKaIe0WMs

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/xbgJHhPqcq

🚨 Type I IFN in Pediatric SLE: Expanded Insights! •🩺 IFN-I Impact: Fuels pediatric SLE; drives T-cell autoreactivity, autoantibody production, proinflammatory cytokines. •📈 Key Pathways: Plasmacytoid dendritic cells overproduce IFN-I via cGAS-STING-TBK1, TLR4/TLR9; https://t.co/4i3MktOoVd

🔬 Proud to present our poster at #EULAR2025! 📌 Serum KL-6 and IL-18 as Diagnostic and Prognostic Biomarkers in Systemic Sclerosis-Associated ILD: A 24-Month Cohort Study KL-6 and IL-18 show promising roles in tracking ILD progression and lung function decline in #SSc 📍F.136 https://t.co/woTMnTkRKY

Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS. https://t.co/E5jlYYHowM